Scilex Holding Company Net Income (Loss) Available to Common Stockholders, Diluted
Scilex Holding Company (SCLX) reported Net Income (Loss) Available to Common Stockholders, Diluted of -$114.73 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2026-08-14
- Scilex Holding Company net income (loss) available to common stockholders, diluted for the quarter ending 2026-06-30 was -$114.73M.
- Scilex Holding Company net income (loss) available to common stockholders, diluted for the quarter ending 2026-03-31 was -$43.27M.
- Scilex Holding Company net income (loss) available to common stockholders, diluted for the quarter ending 2025-12-31 was -$33.11M.
- Scilex Holding Company net income (loss) available to common stockholders, diluted for the quarter ending 2025-09-30 was -$257.23M.
- Scilex Holding Company net income (loss) available to common stockholders, diluted for fiscal 2025 was -$402.49M.
- Scilex Holding Company net income (loss) available to common stockholders, diluted for fiscal 2024 was -$81.70M.
- Scilex Holding Company net income (loss) available to common stockholders, diluted for fiscal 2023 was -$166.98M.
- Scilex Holding Company net income (loss) available to common stockholders, diluted for fiscal 2022 was -$23.36M.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 9 month | Net Income (Loss) Available to Common Stockholders, Diluted 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$114.73M 10-Q · filed 2026-08-14 | -$158.00M 10-Q · filed 2026-08-14 | -$191.11M derived: sum of 3 quarters · filed 2026-08-14 | -$448.35M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | -$43.27M 10-Q · filed 2026-05-20 | -$76.38M derived: sum of 2 quarters · filed 2026-05-20 | -$333.62M derived: sum of 3 quarters · filed 2026-05-20 | -$419.68M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | -$33.11M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-10 | -$290.35M derived: sum of 2 quarters · filed 2026-04-10 | -$376.41M derived: sum of 3 quarters · filed 2026-08-14 | -$402.49M 10-K · filed 2026-04-10 |
| 2025-09-30 | -$257.23M 10-Q · filed 2025-11-14 | -$343.30M derived: sum of 2 quarters · filed 2026-08-14 | -$369.38M 10-Q · filed 2025-11-14 | -$384.73M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | -$86.06M 10-Q · filed 2026-08-14 | -$112.14M 10-Q · filed 2026-08-14 | -$127.50M derived: sum of 3 quarters · filed 2026-08-14 | -$131.88M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | -$26.08M 10-Q · filed 2026-05-20 | -$41.44M derived: sum of 2 quarters · filed 2026-05-20 | -$45.82M derived: sum of 3 quarters · filed 2026-05-20 | -$83.41M derived: sum of 4 quarters · filed 2026-05-20 |
| 2024-12-31 | -$15.36M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-10 | -$19.74M derived: sum of 2 quarters · filed 2026-04-10 | -$57.33M derived: sum of 3 quarters · filed 2026-04-10 | -$81.70M 10-K · filed 2026-04-10 |
| 2024-09-30 | -$4.39M 10-Q · filed 2025-11-14 | -$41.97M derived: sum of 2 quarters · filed 2025-11-14 | -$66.35M 10-Q · filed 2025-11-14 | |
| 2024-06-30 | -$37.58M 10-Q · filed 2025-08-13 | -$61.96M 10-Q · filed 2025-08-13 | ||
| 2023-12-31 | -$74.05M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$109.57M derived: sum of 2 quarters · filed 2025-03-31 | -$136.22M derived: sum of 3 quarters · filed 2025-03-31 | -$166.98M 10-K · filed 2025-03-31 |
| 2023-09-30 | -$35.53M 10-Q · filed 2023-11-14 | -$62.18M derived: sum of 2 quarters · filed 2023-11-14 | -$92.93M 10-Q · filed 2023-11-14 | -$110.81M derived: sum of 4 quarters · filed 2023-11-14 |
| 2023-06-30 | -$26.65M 10-Q · filed 2023-08-11 | -$57.40M 10-Q · filed 2023-08-11 | -$75.29M derived: sum of 3 quarters · filed 2023-08-11 | -$53.78M derived: sum of 4 quarters · filed 2023-11-14 |
| 2023-03-31 | -$30.75M 10-Q · filed 2023-05-12 | -$48.64M derived: sum of 2 quarters · filed 2023-05-12 | -$27.14M derived: sum of 3 quarters · filed 2023-11-14 | -$44.97M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-12-31 | -$17.88M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-07 | $3.62M derived: sum of 2 quarters · filed 2023-11-14 | -$14.22M derived: sum of 3 quarters · filed 2023-11-14 | -$23.36M 10-K · filed 2023-03-07 |
| 2022-09-30 | $21.50M 10-Q · filed 2023-11-14 | $3.66M derived: sum of 2 quarters · filed 2023-11-14 | -$5.48M 10-Q · filed 2023-11-14 | |
| 2022-06-30 | -$17.84M 10-Q · filed 2023-08-11 | -$26.98M 10-Q · filed 2023-08-11 | ||
| 2022-03-31 | -$9.14M 10-Q · filed 2023-05-12 | |||
| 2021-12-31 | -$88.42M 10-K · filed 2023-03-07 | |||
| 2020-12-31 | -$47.52M 10-K · filed 2023-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |